<- Go Home
NKGen Biotech, Inc.
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Market Cap
$6.1M
Volume
1.4M
Cash and Equivalents
$8.0K
EBITDA
-$30.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.19
52 Week Low
$0.10
Dividend
N/A
Price / Book Value
-0.10
Price / Earnings
-0.07
Price / Tangible Book Value
-0.10
Enterprise Value
$36.8M
Enterprise Value / EBITDA
-1.22
Operating Income
-$31.3M
Return on Equity
110.57%
Return on Assets
-97.34
Cash and Short Term Investments
$8.0K
Debt
$30.7M
Equity
-$47.0M
Revenue
N/A
Unlevered FCF
-$29.7M
Sector
Biotechnology
Category
N/A